Abstract
The current evidence to guide adjuvant endocrine therapy in women with ER-positive breast cancer, including tamoxifen, aromatase inhibitors, and ovarian function suppression is reviewed. The studies include ATLAS, aTTom, SOFT, ECOG E3193, TEXT, ABCSG 12, and the Early Breast Cancer Trialists’ Collaborative Group meta-analysis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
